YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Immutep Limited The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment remain o…
The Australian stock market recently experienced a solid performance, buoyed by higher gold and silver prices and a positive close on Wall Street. In the context of these market dynamics, investors might consider exploring opportunities be…
Immutep Limited The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolment Strong operational progress continues globally with over 120 activated clinical sites and 27 countries ha…
We recently published 7 Best ASX Stocks to Buy Right Now. Immutep Limited (NASDAQ:IMMP) is one of the best ASX stocks. Immutep Limited (NASDAQ:IMMP) is a biotechnology company developing therapies for cancer and autoimmune diseases. The fi…
As Australian shares face a challenging start to the week, influenced by global tech sector declines, investors may find themselves exploring alternative opportunities within the market. Penny stocks, often representing smaller or newer co…
Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.Immutep Limited (IMMP): Firm Reports Positive Data from Trials In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from…
Immutep Limited Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 mill…
As the Australian market remains rangebound, with the S&P/ASX 200 index hovering around the 8,500-point mark and showing little sign of a Santa Rally on the horizon, investors are closely monitoring economic indicators like bond yields and…
As the Australian market navigates a period of mixed sentiment, with the S&P/ASX 200 (XJO) rebounding to 8,600 points despite inflation climbing to 3.8%, investors are closely watching sectors like IT which recently lagged behind materials…
The Australian market is experiencing turbulence, with the ASX 200 futures indicating a significant drop following the recent end of the U.S. government shutdown and ongoing economic uncertainties. Despite this volatility, penny stocks con…
Over the last seven days, the Australian market has experienced a 1.5% decline, yet it has risen by 9.4% over the past year with earnings forecasted to grow annually by 12%. In this context, identifying stocks that are trading below their…
The Australian market recently experienced a dip, with the ASX down 0.3% as investors awaited key CPI data and closely monitored geopolitical developments, such as the US-China diplomatic talks. In this environment of cautious optimism and…
Immutep Limited Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysis Over 100 clinical sites across 24 countries now activ…
Australian shares are set to experience a modest rise as trading resumes in New South Wales and Queensland, with ASX 200 futures indicating a slight uptick. In this context, penny stocks remain an intriguing segment of the market, often re…
As the Australian market experiences a slight pullback following a bullish surge, investors are keenly observing the ASX 200's movements amidst fluctuating global economic factors such as U.S. government shutdown concerns and rising gold p…
As the Australian market navigates a fluctuating landscape, with the S&P/ASX 200 Index recently flirting with 8,860 points and foreign direct investment outflows heading back to the US, investors are keenly evaluating high-growth opportuni…
Immutep Limited SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has…
The Australian stock market showed mixed performance recently, with utilities and energy sectors leading gains while financials lagged behind. In this fluctuating landscape, investors may find opportunities in penny stocks—an investment ar…
Immutep Limited SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upc…
The Australian market has experienced a downward trend recently, influenced by the Reserve Bank of Australia's cautious stance on interest rate cuts and uncertainties surrounding upcoming U.S. tariffs. In this environment, identifying high…
Immutep Limited (NASDAQ:IMMP) is one of the 7 Best ASX Stocks to Buy Now. On June 23, Immutep Limited (NASDAQ:IMMP) announced positive initial efficacy data and continued favourable safety data from the placebo-controlled, double-blind fir…
The Australian market has shown resilience with the ASX200 closing up 0.58% following a rate cut by the RBA, and the IT sector leading gains with a 2.3% increase, indicating positive sentiment towards technology stocks amidst broader econo…
Qualcomm downgraded, Wingstop upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compile…
Immutep Limited Media Release SYDNEY, AUSTRALIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for can…
Immutep Limited Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational trial in 1st line non-small cell lung cancer (1L NSCLC) TACTI-003 Phase IIb –…
Immutep Limited Media Release Mini Oral presentation will include datafromTACTI-002 Phase II trialevaluating chemotherapy-free IO combination of efti plus KEYTRUDA® (pembrolizumab) Two additional posters on investigator-initiated trials ev…
Immutep Limited Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for can…
Key Insights Significantly high institutional ownership implies Immutep's stock price is sensitive to their trading actions The top 10 shareholders own 50% of the company Analyst forecasts along with ownership data serve to give a strong i…
Immutep Limited Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, t…
Immutep Limited Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for can…
Immutep Limited Media Release SYDNEY, AUSTRALIA, June 20, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, t…
While the idea of acquiring the best penny stocks under $3 may appeal to your inner contrarian, you need to first understand the risks. In most cases, shares that trade this low do so for a reason, and typically not a good one. On a psycho…
By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. Just take a look at Immutep Limited (ASX:IMM),…
Immutep Limited SYDNEY, AUSTRALIA, June 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoim…
Immutep Limited Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in TACTI-002 Phase II Promising…
Immutep Limited Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the Company), is pleased to announce the successful completion of an institutional placement…